Abstract
The effects of angiotensin II type 1 receptor blockers (ARBs) on cerebral blood flow (CBF) autoregulation have not been fully clarified. Thus, we examined the acute effect of valsartan, the most selective ARB, on CBF autoregulation in spontaneously hypertensive rats. Intravenous administration of valsartan (0.3 mg/kg) reduced the mean arterial pressure (MAP) from 184±5 (mean±SEM) to 174±5 mmHg (p<0.001) without affecting CBF as measured by laser-Doppler flowmetry. The lower limit of CBF autoregulation (the MAP at which the CBF was 80% of the baseline value) in the valsartan-treated group (122±3 mmHg) was significantly lower than that in the control group (135±4 mmHg, p<0.05). Reverse transcribed–polymerase chain reaction and immunohistochemical staining demonstrated that both angiotensin II type 2 receptors and angiotensin II type 1 receptors (AT1Rs) were expressed in endothelial and smooth muscle cells of the rat cerebral arteries. These results suggest that specific inhibition of AT1Rs in the cerebral circulation causes the leftward shift of the lower limit of autoregulation.
Similar content being viewed by others
Article PDF
References
Suzuki H, Kanno Y : Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307–314.
Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
Nakamura T, Kanno Y, Takenaka T, Suzuki H : An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res 2005; 28: 415–423.
Takeuchi K, Ideishi M, Tashiro T, et al: Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers. Hypertens Res 2005; 28: 639–644.
Barry DI, Paulson OB, Jarden JO, Juhler M, Graham DI, Strandgaard S : Effects of captopril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 1984; 76: 79–85.
Bray L, Lartaud I, Muller F, Atkinson J, Capdeville C : Effects of the angiotensin I converting enzyme inhibitor perindopril on cerebral blood flow in awake hypertensive rats. Am J Hypertens 1991; 4: 246S–252S.
Cai H, Yao H, Ibayashi S, et al: Effects of long-acting angiotensin-converting enzyme inhibitor, imidapril, on the lower limit of cerebral blood flow autoregulation in hypertensive rats. Eur J Pharmacol 1998; 341: 73–77.
Lartaud I, Makki T, Bray-des-Boscs L, et al: Effect of chronic ANG I–converting enzyme inhibition on aging processes. IV. Cerebral blood flow regulation. Am J Physiol 1994; 267: R687–R694.
Muller F, Lartaud I, Bray L, et al: Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, restores the lower limit of autoregulation of cerebral blood flow in the awake renovascular hypertensive rat. J Hypertens 1990; 8: 1037–1042.
Torup M, Waldemar G, Paulson OB : Ceranapril and cerebral blood flow autoregulation. J Hypertens 1993; 11: 399–405.
Naveri L, Stromberg C, Saavedra JM : Angiotensin II AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319. J Cereb Blood Flow Metab 1994; 14: 38–44.
Vraamark T, Waldemar G, Strandgaard S, Paulson OB : Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. J Hypertens 1995; 13: 755–761.
Oku N, Kitagawa K, Imaizumi M, et al: Hemodynamic influences of losartan on the brain in hypertensive patients. Hypertens Res 2005; 28: 43–49.
Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J : Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761–771.
de Gasparo M, Whitebread S : Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept 1995; 59: 303–311.
Nishimura Y, Ito T, Saavedra JM : Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478–2486.
Tsutsumi K, Saavedra JM : Characterization of AT2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991; 261: H667–H670.
Toyoda K, Fujii K, Ibayashi S, Nagao T, Kitazono T, Fujishima M : Role of nitric oxide in regulation of brain stem circulation during hypotension. J Cereb Blood Flow Metab 1997; 17: 1089–1096.
Zaharchuk G, Mandeville JB, Bogdanov AA Jr, Weissleder R, Rosen BR, Marota JJ : Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 1999; 30: 2197–2204.
Verhaegen MJ, Todd MM, Hindman BJ, Warner DS : Cerebral autoregulation during moderate hypothermia in rats. Stroke 1993; 24: 407–414.
Takada J, Ibayashi S, Nagao T, Ooboshi H, Kitazono T, Fujishima M : Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats. Stroke 2001; 32: 1216–1219.
Kitayama J, Kitazono T, Ibayashi S, et al: Role of phosphatidylinositol 3-kinase in acetylcholine-induced dilatation of rat basilar artery. Stroke 2000; 31: 2487–2493.
Ago T, Kitazono T, Ooboshi H, et al: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227–233.
Kramer C, Sunkomat J, Witte J, et al: Angiotensin II receptor–independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770–776.
Campbell DJ : Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Clin Exp Pharmacol Physiol 1995; 22: 903–911.
Kitazono T, Ibayashi S, Nagao T, Fujii K, Kagiyama T, Fujishima M : Role of tyrosine kinase in dilator responses of rat basilar artery in vivo. Hypertension 1998; 31: 861–865.
Katada J, Majima M : AT2 receptor–dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002; 136: 484–491.
Sosa-Canache B, Cierco M, Gutierrez CI, Israel A : Role of bradykinins and nitric oxide in the AT2 receptor–mediated hypotension. J Hum Hypertens 2000; 14 ( Suppl 1): S40–S46.
Tsutsumi Y, Matsubara H, Masaki H, et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925–935.
Cai H, Yao H, Ibayashi S, Takaba H, Fujishima M : Amlodipine, a Ca2+ channel antagonist, modifies cerebral blood flow autoregulation in hypertensive rats. Eur J Pharmacol 1996; 313: 103–106.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takada, J., Ibayashi, S., Ooboshi, H. et al. Valsartan Improves the Lower Limit of Cerebral Autoregulation in Rats. Hypertens Res 29, 621–626 (2006). https://doi.org/10.1291/hypres.29.621
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.621
Keywords
This article is cited by
-
Crosstalk between the angiotensin and endothelin system in the cerebrovasculature after experimental induced subarachnoid hemorrhage
Neurosurgical Review (2018)
-
Bradykinin Antagonist Counteracts the Acute Effect of Both Angiotensin-Converting Enzyme Inhibition and of Angiotensin Receptor Blockade on the Lower Limit of Autoregulation of Cerebral Blood Flow
Journal of Cerebral Blood Flow & Metabolism (2014)
-
Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke
Hypertension Research (2012)
-
Cerebral dysautoregulation and the risk of ischemic events in occlusive carotid artery disease
Journal of Neurology (2008)
